Why should you invest with us?

• Our therapeutic hypothesis  is strongly validated by the  results of the pre-clinical studies

• Our Chief Scientific Officer is  uniquely highly qualified to lead scientific strategy and operations

• There is potential for  extremely high financial returns

Our team brings extensive expertise in PKCbeta biology, metabolic disease models, medicinal chemistry, and small-molecule development. We are well positioned to collaborate on IND-directed PK/PD and toxicity studies, NHP efficacy studies, and Phase I IND preparation. Our program may also benefit from the FDA Animal Rule and the potential for Priority Review Vouchers for Obesity and fatty liver indications.

We are interested in collaborating with a major pharmaceutical company to participate in our recent drug-development efforts, which highlight next-generation compounds such as INST3399 and its analogs. These compounds demonstrate greater potency and selectivity for PKCbeta, and INST3399 in particular is emerging as a promising therapeutic agent for obesity, with evidence showing its ability to reduce body weight, adiposity, and fatty liver by targeting key pathways involved in energy homeostasis.

Investment Inquiry & Contact:

Email: mehta.80@osu.edu
Telephone: (614) 915-9079